期刊文献+

甲状腺功能亢进性肝损害的临床特点分析 被引量:3

Analysis of the clinical characteristics of hyperthyroidism liver damage
下载PDF
导出
摘要 目的:探讨甲状腺功能亢进(简称甲亢)合并肝损害患者的临床表现特点。方法:收治甲亢患者100例,将甲亢合并肝损害患者作为观察组,将甲亢无肝损害患者作为对照组,比较两组的临床资料。结果:观察组平均年龄、肝功能各项指标与甲状腺功能各项指标均明显高于对照组(P<0.05)。甲亢性肝损害与甲亢病程相关(P<0.05)。结论:年龄较大,甲亢严重以及病程较长的患者易发甲状腺功能性亢进肝损害,其临床症状没有典型性,控制甲亢的同时也应进行保肝治疗。 Objective:To explore the clinical features of patients with hyperthyroidism and liver damage.Methods:100 patients with hyperthyroidism were selected,the patients with hyperthyroidism and liver damage were selected as the observation group,the patients with hyperthyroidism and no liver damage were used as the control group,we compared the clinical data of two groups.Results:In the observation group,the average age,all indexes of liver function and the indexes of thyroid function were significantly higher than those of the control group(P<0.05).Hyperthyroidism liver damage was associated with the course of hyperthyroidism(P<0.05).Conclusion:Patients with older age,severe hyperthyroidism and longer course of disease were prone to hyperthyroidism liver damage,its clinical symptoms were not typical,and the control of hyperthyroidism should also be taken to protect the liver,while controlling hyperthyroidism,we should also carry out the treatment of liver protection.
作者 关谊
出处 《中国社区医师》 2018年第6期19-19,21,共2页 Chinese Community Doctors
关键词 甲状腺功能亢进 肝损害 临床特点 Hyperthyroidism Liver damage Clinical characteristics
  • 相关文献

参考文献3

二级参考文献37

  • 1孙红,陈莎,段艺,艾洪武,胡红兵,游上游.血清胱抑素C在儿童肾脏疾病中的应用研究[J].微循环学杂志,2005,15(4):31-32. 被引量:40
  • 2段敏虹,陈广原,张彤.甲状腺功能亢进症患者肝功能变化的相关因素分析[J].中国医师进修杂志(内科版),2006,29(6):53-54. 被引量:24
  • 3Bahn Chair RS,Burch HB,Cooper DS,et al.Hyperthyroidism and other causes of thyrotoxicosis:management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists[J].Thyroid,2011,21(6):593-646.
  • 4George J.Kahaly,Luigi Bartalena,et al.The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis:a European perspective[J].Thyroid,2011,21(6):585-591.
  • 5Yamashita S,Amino N,Shong YK.The American Thyroid Association and American Association of Clinical Endocrinologists hyperthyroidism and other causes of thyrotoxicosis guidelines:viewpoints from Japan and Korea[J].Thyroid,2011,21(6):577-580.
  • 6Cooper DS,Doherty GM,Haugen BR,et al.American Thyroid Association(ATA)Guidelines Taskforce on thyroid nodules and differentiated cancer[J].Thyroid,2009,19(11)1167-1214.
  • 7Trdisk F,Tallstedt L,Abraham-Nordling M,et al.Thyroidassociated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131[J].J Clin Endocrinol Metab,2009,94(10):3700-3707.
  • 8Peters H,Fischer C,Bogner U,et al.Radioiodine therapy of Graves' hyperthyroidism:standard vs.calculated 131 iodine activity.Results from aprospective,randomized,multicentre study[J].Eur J Clin Invest,1995,25(3):186-193.
  • 9Costaghola S,Morgenthaler NG,Hoermann R,et al.Second generation assay for thyrotropin receptor antibodies has superior diagnostics ensitivity for Graves' disease[J].J Clin Endocrinol Metab,1999,84(1):90-97.
  • 10Cooper DS.Antithyroid drugs[J].N Engl J Med,2005,352(9):905-917.

共引文献43

同被引文献22

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部